Do GLP-1 Medications Affect Your Sex Drive?

GLP-1 medications are usually discussed in terms of appetite, weight and blood sugar. But another question is increasingly part of the conversation:

Can medications such as Ozempic®, Wegovy® or Zepbound® change your sex drive?

Some people describe less interest in sex after starting treatment. Others say the opposite. And some notice changes in erections, arousal or orgasm rather than sexual desire itself.

So what does the research actually show?

The short answer

We don't have a definitive answer yet.

Current evidence has not established that GLP-1–based medications consistently increase or decrease sexual desire.

A 2026 narrative review in Sexual Medicine Reviews looked specifically at GLP-1 receptor agonists and sexual function in women and men. The authors found that human evidence remains limited and mixed, with outcomes potentially influenced by factors including metabolic health, medication type, sex and psychosocial factors. Read the review in Sexual Medicine Reviews.

That distinction matters.

A change that happens while taking a medication is not necessarily a change caused by that medication.

Sexual wellbeing can be influenced by physical health, hormones, other medications, mood, energy, sleep, relationships, body image, stress and many other factors.

First, what are GLP-1 medications?

GLP-1–based medications are used for conditions including type 2 diabetes and chronic weight management.

Two active ingredients appear frequently in the current conversation:

• Semaglutide is the active ingredient in Ozempic and Wegovy.
• Tirzepatide is the active ingredient in Zepbound and Mounjaro.

Semaglutide is a GLP-1 receptor agonist.

Tirzepatide is somewhat different: it acts on both GIP and GLP-1 receptors, although it is commonly included in the broader public conversation around GLP-1–based medications.

It is also important not to treat brand names as interchangeable. Ozempic and Wegovy contain semaglutide but are different prescription products with different FDA-approved indications. The same is true of Zepbound and Mounjaro, which both contain tirzepatide.

Can semaglutide affect libido?

Researchers have begun looking more closely at this question, but the findings don't support a simple yes-or-no conclusion.

A 2025 cross-sectional analysis published in the International Journal of Impotence Research evaluated reports submitted to the FDA Adverse Event Reporting System, or FAERS. Researchers examined reports involving male sexual dysfunction among people using GLP-1 receptor agonists, including reports involving erectile dysfunction, decreased libido and orgasmic dysfunction. View the study on PubMed.

That sounds concerning at first—but the type of study matters.

FAERS is a pharmacovigilance system designed to identify potential safety signals. A report submitted to the system does not establish that a medication caused the reported event, and these data cannot tell us how often an effect occurs among everyone taking a medication.

The broader evidence is also not one-directional.

A randomized, double-blind, placebo-controlled crossover study published in EBioMedicine examined the GLP-1 receptor agonist dulaglutide in healthy men. Researchers did not find an effect on sexual desire in the study population. View the study on PubMed.

The medications and populations in these studies are different, so the findings shouldn't simply be applied to everyone taking semaglutide. But together they illustrate why broad claims such as “GLP-1s lower your libido” aren't supported by the evidence we currently have.

What about Zepbound and tirzepatide?

Research involving tirzepatide makes the picture even more complicated.

A 2025 retrospective cohort study published in the Journal of Diabetes and its Complications examined erectile-dysfunction diagnoses among men with type 2 diabetes. In that population, tirzepatide was associated with a lower risk of erectile dysfunction compared with sitagliptin, injectable semaglutide and dulaglutide.

Importantly, the researchers did not conclude that tirzepatide prevents or treats erectile dysfunction. They specifically called for randomized trials to confirm the finding and investigate possible explanations. View the study on PubMed.

This is an important example of how easily research can be oversimplified online.

The study does not mean:

“Zepbound improves sexual function.”

And reports of reduced libido do not mean:

“Zepbound lowers sexual desire.”

Both conclusions would go beyond the available evidence.

Why might your sex life feel different while taking a GLP-1?

This may be the more useful question.

When someone starts a GLP-1–based medication, the medication is rarely the only thing changing.

Weight, appetite, eating habits, physical health, energy, confidence and other aspects of everyday life may change at the same time.

That makes cause and effect difficult to separate.

Appetite and how you feel physically

GLP-1–based medications can change appetite and food intake, and gastrointestinal effects such as nausea can occur.

If someone feels nauseated, uncomfortable or simply different physically, their interest in intimacy may also feel different.

That doesn't necessarily mean the medication has directly changed the biological pathways controlling sexual desire.

Metabolic health

Sexual health and metabolic health can overlap.

Conditions such as obesity and type 2 diabetes are themselves associated with factors that can affect sexual function. Researchers are therefore trying to determine how much of any observed change during GLP-1 treatment comes from the medication itself and how much may relate to changing metabolic health.

A 2026 systematic review in The Journal of Sexual Medicine examined GLP-1 receptor agonists and male reproductive outcomes. Across the studies reviewed, researchers observed potentially favorable changes in some hormonal and reproductive measures in men with metabolic conditions, but emphasized that longer-term controlled studies are still needed. View the review on PubMed.

This research concerns reproductive and hormonal outcomes—not proof of increased libido—but it helps illustrate why the biological picture is more complicated than “GLP-1 equals lower sex drive.”

Confidence and body image

Weight changes can also change how someone feels about their body and intimacy.

For some people, those changes may coincide with greater confidence. For others, rapid changes in their body can require adjustment.

These experiences can affect someone's sex life without telling us whether a medication directly changed sexual desire.

Mood, stress, sleep and relationships

Sexual interest doesn't exist independently from the rest of life.

Stress, mood, sleep, relationship dynamics and other medications can all change around the same time someone begins treatment.

That's one reason timing alone cannot establish causation.

Can GLP-1 medications increase sex drive?

Some people report that experience.

But the same caution applies in both directions.

Feeling more interested in sex after starting a GLP-1 medication does not establish that the medication increased libido.

Weight change, health changes, confidence, mobility, relationships and many other variables may be changing simultaneously.

The 2026 Sexual Medicine Reviews review found exactly this kind of mixed picture in the available human evidence: some reports describe enhanced libido, while others describe decreased desire or other sexual-function changes. The authors concluded that more controlled research is needed. Read the review.

Desire, arousal, erections and orgasm are not the same thing

This is one of the most important parts of the GLP-1 and sex-drive conversation.

People often use “libido” to describe almost any change in their sex life.

But sexual response has different components.

Desire is your interest in sexual activity.

Arousal involves the mental and physical processes associated with becoming sexually excited.

Erectile function is the ability to develop and maintain an erection.

Orgasm is another distinct component of sexual response.

Those things can change independently.

Someone can want sex but have difficulty with physical arousal. Someone else can have normal erectile function but little interest in sex. Another person may experience desire and arousal but notice a change in orgasm.

This distinction is particularly important when trying to understand whether something changed after starting a medication.

Instead of asking only:

“Did my libido change?”

It can be more useful to ask:

“What part of my sexual response changed?”

What does the research say about GLP-1s and orgasm?

There is very little clinical research here.

A 2025 case report in the journal Sexual Medicine described anorgasmia and reduced arousal in a postmenopausal woman after treatment with GLP-1 receptor agonists. Symptoms and medication exposure changed over time, leading the authors to propose several possible mechanisms. Read the case report in Sexual Medicine.

But this was one patient.

Case reports are useful because they can identify questions that deserve further investigation. They cannot establish that the same effect will happen to other patients or determine how common an effect may be.

The authors themselves concluded that further research is needed.

What about semaglutide and erectile dysfunction?

This has also been studied, but again the evidence needs context.

A retrospective database study published in the International Journal of Impotence Research examined non-diabetic men ages 18 to 50 with obesity. Researchers found an association between semaglutide prescriptions and subsequent erectile-dysfunction diagnoses or PDE5-inhibitor prescriptions compared with a matched control group. View the study.

This was an observational database study.

It therefore identifies an association, not proof that semaglutide caused erectile dysfunction.

Other research, including the tirzepatide study discussed earlier, has produced findings pointing in a different direction in different patient populations.

For now, there isn't enough evidence to turn either finding into a universal conclusion about GLP-1–based medications and erectile function.

So, do GLP-1s “kill your sex drive”?

Current evidence does not support that blanket claim.

Researchers have identified reports and associations involving libido, erections, arousal and orgasm. Other studies have found no effect on desire or have observed potentially favorable sexual or reproductive outcomes in particular populations.

The most current broad review of this area describes the human evidence as mixed and limited. Merhi, Sexual Medicine Reviews, 2026.

So the scientifically responsible answer today is:

GLP-1–based medications may coincide with changes in sexual wellbeing for some people, but research has not established a predictable effect on sex drive across patients.

What if your sex drive changed after starting Ozempic, Wegovy or Zepbound?

Don't automatically assume the medication is responsible—but don't ignore the change either.

It can help to think more specifically about what has changed:

• Is your desire different?
• Is physical arousal different?
• Have erections changed?
• Has orgasm changed?
• When did you first notice it?
• Did anything else change around the same time?

A healthcare professional may also consider your health history, other medications, metabolic health, hormones when relevant, sleep, stress and other potential contributors.

And don't stop or change a prescription medication based only on something you read online. Medication changes should be discussed with the clinician managing your care.

Frequently Asked Questions

Does Ozempic cause low libido?

Research has not established that Ozempic or semaglutide consistently causes low libido. Some observational and pharmacovigilance research has identified sexual-function reports or associations, but these types of studies cannot establish that the medication caused the change.

Does Wegovy affect sex drive?

There isn't currently enough evidence to conclude that Wegovy predictably increases or decreases sexual desire. Human research on GLP-1 receptor agonists and libido remains limited and mixed.

Does Zepbound cause low sex drive?

Research has not established low libido as a predictable effect of tirzepatide. Studies examining tirzepatide and sexual function remain limited, and individual experiences may have many possible contributors.

Can GLP-1 medications increase libido?

It is possible for someone to report increased sexual interest while taking a GLP-1–based medication, but that does not prove the medication directly caused the change. Improvements in health, confidence, mobility or other factors may occur simultaneously.

Can semaglutide cause erectile dysfunction?

A retrospective study found an association between semaglutide prescriptions and erectile-dysfunction outcomes in a specific population of younger non-diabetic men with obesity. Because the study was observational, it cannot establish that semaglutide caused erectile dysfunction.

Does Ozempic affect testosterone?

Researchers are investigating GLP-1 receptor agonists and reproductive hormones. Some studies have observed changes in testosterone in men with obesity or metabolic conditions, but those findings should not be interpreted to mean that semaglutide is a testosterone treatment or that the same effect occurs in everyone.

Are libido and erectile function the same thing?

No. Libido refers to sexual desire, while erectile function is a physical component of sexual response. It is possible to experience low desire with normal erectile function—or erectile difficulties while still having sexual desire.

Can GLP-1 medications affect orgasm?

There is very limited evidence. A published case report has described anorgasmia associated in time with GLP-1 receptor-agonist treatment, but a case report cannot establish causation or determine how commonly this occurs.

Should I stop my GLP-1 if my sex drive changes?

Do not stop or change a prescription medication without discussing it with the healthcare professional managing your treatment. Changes in sexual wellbeing can have many possible causes.

‍

AmalfiDuo Sexual Wellness Programs

If you’re exploring ways to support your sexual wellness, AmalfiDuo offers private, provider-guided care programs for adults.

Explore available programs and complete a private online health evaluation if you find an option that may be right for you. A licensed clinician will review your health information to determine whether treatment is appropriate.

Explore Sexual Wellness Programs

A prescription is never guaranteed.

‍

References

1. Merhi Z. GLP-1 receptor agonists and sexual function in women and men: a narrative review of emerging evidence and the need for further research. Sexual Medicine Reviews. 2026;14(1). View article
2. Pourabhari Langroudi A, Chen AL, Basran S, et al. Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data. International Journal of Impotence Research. 2025;37(8):661–667. View on PubMed
3. Lengsfeld S, Probst L, Emara Y, et al. Effects of the glucagon-like peptide-1 receptor agonist dulaglutide on sexuality in healthy men: a randomised, double-blind, placebo-controlled crossover study. EBioMedicine. 2024;107:105284. View on PubMed
4. Cowart K, Murphy C, Carris NW. Association of tirzepatide with erectile dysfunction in people with type 2 diabetes. Journal of Diabetes and its Complications. 2025;39(10):109116. View on PubMed
5. Visvabharathy V, MacPhedran S, Shupp K, King B. Anorgasmia following initiation of GLP-1 agonist. Sexual Medicine. 2025;13(3). View article
6. Able C, Liao B, Saffati G, et al. Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study. International Journal of Impotence Research. 2025;37:315–319. View on PubMed
7. Deameh MG, Ramez M, Rowaiee R, et al. Effects of glucagon-like peptide-1 receptor agonists on male reproductive hormones, semen parameters, and metabolic outcomes: a systematic review. The Journal of Sexual Medicine. 2026;23(2). View on PubMed

‍

This article is for general educational purposes only and is not a substitute for individualized medical advice, diagnosis or treatment. Always discuss medication questions and changes in sexual health with a qualified healthcare professional. AmalfiDuo Journal articles are written by AmalfiDuo Editorial and are not medically reviewed — see our Editorial Policy.

Ozempic® and Wegovy® are registered trademarks of Novo Nordisk. Zepbound® is a registered trademark of Eli Lilly and Company. AmalfiDuo is not affiliated with or endorsed by these companies.

‍